Current approaches to luteal phase management in an in-vitro fertilization program


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The paper discusses luteal phase (LP) defect in controlled ovarian hyperstimulation cycles: the causes and mechanisms of LP defect and the impact of different LP support regimens using progesterone preparations, human chorionic gonadotropin, estrogens, or a gonadotropin-releasing hormone (GnRH) agonist on the results of an in-vitro fertilization program. It gives data on a novel combined LP management regimen (with a GnRH agonist and micronized progesterone). The paper discusses the efficiency of this regimen versus the standard LP support regimen and the possible mechanisms of action of GnRH agonists on the endometrium, embryo, and corpus luteum.

全文:

受限制的访问

作者简介

E. Gallyamova

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: nikson2003@inbox.ru
postgraduate

S. Perminova

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: perisvet@list.ru
Doctor of Medical Science, leading research worker of the 1st gynecology department

E. Durinyan

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: evelina_durinyan@mail.ru
Candidate of Medicine, medical doctor of the 1st gynecology department

E. Mityurina

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: mity-elena@yandex.ru
postgraduate

参考

  1. Ferraretti A., Goossens V., Bhattacharya S. et al. Assisted reproductive technology in Europe, 2010: results generated from European registers by ESHER. Preliminary results. In: European Society of Human Reproduction and Embryology: 29 Annual Meeting. London, United Kindom, 7-10 July 2013.
  2. Алексеева М.Л., Екимова Е.В., Колодько В.Г., Фанченко Н.Д., Понкратова Т.С. Хорионический гонадотропин. Структура, функция, диагностическая значимость. Проблемы репродукции. 2006; 3: 7-14.
  3. Fatеmi H.M., Popovic-Todorovic B., Papanikolaou E., Donoso P., Devroey P. An update of luteal phase support in stimulated IVF cycles. Hum. Reprod. Update. 2007; 13(6): 581-90.
  4. Penzias A.S. Luteal phase support. Fertil. Steril. 2002; 77: 318-23.
  5. Rosenberg S.M., Luciano A.A., Riddick D.H. The luteal phase defect: the relative frequency of, and encouraging response to, treatment with vaginal progesterone. Fertil. Steril. 1980; 34: 17-20.
  6. Kolibianakis E.M., Devroey P. The luteal phase after ovarian stimulation. Reprod. Biomed Online. 2002; 5(Suppl. 1): 26-35.
  7. Белобородов С.М. Тактика поддержки лютеиновой фазы в программах ВРТ-современные тенденции. Проблемы репродукции. 2003; 4: 43-6.
  8. Edwards R.G., Steptoe P.C., Purdy J.M. Establishing full-term human pregnancies using cleaving embryos grown in vitro. Br. J. Obstet. Gynaecol. 1980; 87: 737-56.
  9. Ревишвили Н.А. Особенности течения лютеиновой фазы индуцированного цикла и принципы медикаментозной терапии: Автореф. дис.. канд. мед. наук. М.; 2005.
  10. Kerin J.F., Broom T.J., Ralph M.M., Kerin J.F., Broom T.J., Ralph M.M. et al. Human luteal phase function following oocyte aspiration from the immediately preovular graafian follicle of spontaneous ovulation cycles. Br. J. Obstet. Gynaecol. 1981; 88(10): 1021-8.
  11. Miyake A., Aono T., Kinugasa T., Tanizawa O., Kurachi K. Suppression of serum levels of luteinizing hormone by short- and long-loop negative feedback in ovariectomized women. J. Endocrinol. 1979; 80(3): 353-6.
  12. Tavaniotou A., Devroey P. Effect of human chorionic gonadotropin on luteal luteinizing hormone concentrations in natural cycles. Fertil. Steril. 2003; 80: 654-5.
  13. Elter K., Nelson L.R. Use of third generation gonadotropin-releasing hormone antagonists in in vitro fertilization-embryo transfer: a review. Obstet. Gynecol. Surv. 2001; 56: 576-88.
  14. Ragni G., Vegetti W., Baroni E., Colombo M., Arnoldi M., Lombroso G., Crosignani P.G. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist. Hum. Reprod. 2001; 16: 2258-62.
  15. Beckers N.G., Macklon N.S., Eijkemans M.J., Ludwig M., Felberbaum R.E., Diedrich K. et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J. Clin. Endocrinol. Metab. 2003; 88: 4186-92.
  16. Амирова А.А., Назаренко Т.А., Мишиева Н.Г. Факторы влияющие на исходы ЭКО (обзор литературы). Проблемы репродукции. 2010; 1: 72-3.
  17. Tesarik J., Hazout A., Mendoza-Tesarik R., Mendoza N., Mendoza C. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum. Reprod. 2006; 21(10): 2572-9.
  18. Kyrou D., Kolibianakis E.M., Fatemi H.M., Tarlatzi T.B., Devroey P., Tarlatzis B.C. Increased live birth rates with GnRH agonist addition for luteal support in ICSI/IVF cycles: a systematic review and meta-analysis. Hum. Reprod. Update. 2011; 17(6): 734-40.
  19. OliveiraJ.B.,Baruffi R.,Petersen C.G., Mauri A.L., Cavagna M., Franco J.G. Jr. Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis. Reprod. Biol. Endocrinol. 2010; 8: 107. doi: 10.1186/1477-7827-8-107.
  20. Van der Linden M., Buckingham K., Farquhar C., Kremer J.A., Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst. Rev. 2011; (10): CD009154. doi: 10.1002/14651858.CD009154.pub2.
  21. Chakravarty B.N., Shirazee H.H., Dam P., Goswami S.K., Chatterjee R., Ghosh S. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: Results of a randomised study. J. Steroid Biochem. Mol. Biol. 2005; 97(5): 416-20.
  22. Ganesh A., Chakravorty N., Mukherjee R., Goswami S., Chaudhury K., Chakravarty B. Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertil. Steril. 2011; 95(6): 1961-5. doi: 10.1016/ j.fertnstert.2011.01.148
  23. Dal Prato L., Bianchi L., Cattoli M., Tarozzi N., Flamigni C., Borini A. Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reprod. Biomed. Online. 2008; 16(3): 361-7.
  24. Yanushpolsky E., Hurwitz S., Greenberg L., Racowsky C., Hornstein M. Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization-embryo transfer cycles: A prospective randomized study. Fertil. Steril. 2010; 94(7): 2596-9.
  25. Meyer W.R., Novothy D.B., Fritz M.A., Beyler S.A., Wolf L.J., Lessey B.A. Effect of exogenous gonadotropins on endometrial maturation in oocyte donors. Fertil. Steril. 1999; 71: 109-14.
  26. Киндарова Л.Б., Калинина Е.А., Смольникова В.Ю. Поддержка после периода переноса эмбрионов в программе ЭКО и ПЭ. Акушерство и гинекология. 2003; 4: 50-2.
  27. Fatemi H.M., Kolibianakis E.M., Camus M., Tournaye H., Donoso P., Papanikolaou E. et al. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: A randomized controlled trial. Hum. Reprod. 2006; 21(10): 2628-32.
  28. Ceyhan S.T., Basaran M., Kemal Duru N., Yilmaz A., Goktolga U., Baser I. Use of luteal estrogen supplementation in normal responder patients treated with fixed multidose GnRH antagonist: a prospective randomized controlled study. Fertil. Steril. 2008; 89(6): 1827-30.
  29. Serna J., Cholquevilque J.L., Cela V., Martinez-Salazar J., Requena A., Garcia-Velasco J.A. Estradiol supplementation during the luteal phase of IVF-ICSI patients: a randomized, controlled trial. Fertil. Steril. 2008; 90(6): 2190-5.
  30. Gorkemli H., Ak D., Akyurek C., Aktan M., Duman S. Comparison of pregnancy outcomes of progesterone or progesterone plus estradiol for luteal phase support in ICSIET cycles. Gynecol. Obstet. Invest. 2004; 58(3): 140-4.
  31. Krause B., Ohlinger R. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with GnRH agonist in cases with polyfollicu-lar development. Eur. J. Obstet. Gynecol. Reprod. Biol. 2006;126: 87-92.
  32. Caligara C., Carranza F., Ramos J., Rodriguez I., Gonzalez A., Fernandez-Sanchez M. Luteal phase support in IVF patients at low risk for OHSS: Progesterone vs. progesterone plus HCG. A prospective randomized study. Fertil. Steril. 2007; 88: S163 (abstr.P-166).
  33. Ludwig M., Finas A., Katalinic A., Strik D., Kowalcek I., Schwartz P. et al. Prospective, randomized study to evaluate the success rates using hCG, vaginal progesterone or a combination of both for luteal phase support. Acta Obstet. Gynecol. Scand. 2001; 80: 574-82.
  34. Fujii S., Sato S., Fukui A., Kimura H., Kasai G., Saito Y. Continuous administration of gonadotrophin-releasing hormone agonist during the luteal phase in IVF. Hum. Reprod. 2001; 16(8): 1671-5.
  35. Isikoglu M., Ozgur K., Oehninger S. Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection. J. Reprod. Med. 2007; 52(7): 639-44.
  36. Ata B., Yakin K., Balaban B., Urman B. GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Hum. Reprod. 2008; 23: 668-73.
  37. Isik A.Z., Caglar G.S., Sozen E., Akarsu C., Tuncay G., Ozbicer T., Vicdan K. Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reprod. Biomed. Online. 2009; 19: 472-7.
  38. Qublan H., Amarin Z., Al-Quda M., Diab F., Nawasreh M., Malkawi S. et al. Luteal phase support with GnRH-a improves implantation and pregnancy rates in IVF cycles with endometrium of [less-than or equal to]7 mm on day of egg retrieval. Hum. Fertil. 2008; 11(1): 43-7.
  39. Razieh D.F., Maryam A.R., Nasim T. Beneficial effect of luteal-phase gonadotropin-releasing hormone agonist administration on implantation rate after intracytoplasmic sperm injection. Taiwan J. Obstet. Gynecol. 2009; 48: 245-8.
  40. Inamdar D.B., Majumdar A. Evaluation of the impact of gonadotropin leasing hormone agonist as an adjuvant in luteal-phase support on IVF outcome. J. Hum. Reprod. Sci. 2012; 5(3): 279-84. doi: 10.4103/09741208.106341.
  41. Ata B., Urman B. Single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles: is the effect dependent on the type of GnRH analogue used for pituitary suppression? Reprod. Biomed. Online. 2010; 20: 165-6.
  42. Kawamura K., Fukuda J., Kumagai J., Shimizu Y., Kodama H., Nakamura A., Tanaka T. Gonadotropin-releasing hormone I analog acts as an antiapoptotic factor in mouse blastocysts. Endocrinology. 2005; 146: 4105-16.
  43. Raga F., Casan E.M., Kruessel J.S., Wen Y., Huang H.Y., Nezhat C., Polan M.L. Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle. Biol. Reprod. 1998; 59: 661-9.
  44. Raga F., Casan E.M., Wen Y., Huang H.Y., Bonilla-Musoles F., Polan M.L. Independent regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-3 in human endometrial stromal cells by gonadotropin-releasing hormone: implications in early human implantation. J. Clin. Endocrinol. Metab. 1999; 84: 636-42.
  45. Klemmt P.A., Liu F., Carver J.G., Jones C., Brosi D., Adamson J. et al. Effects of gonadotropin releasing hormone analogues on human endometrial stromal cells and embryo invasion in vitro. Hum. Reprod. 2009; 24: 2187-92.
  46. Tesarik J., Hazout A., Mendoza C. Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum. Reprod. 2004; 19(5): 1176-80.
  47. Iwashita M., Kudo Y., Shinozaki Y., Takeda Y. Gonadotropin-releasing hormone increases serum human chorionic gonadotropin in pregnant women. Endocr. J. 1993; 40(5): 539-44.
  48. Lin L., Roberts V.J., Yen S. Expression of human gonadotropin-releasing hormone receptor gene in the placenta and its functional relationship to human chorionic gonadotropin secretion. J. Clin. Endocrinol. Metab. 1995; 80: 580-5.
  49. Siler-Khodr T.M., Smikle C.B., Sorem K.A., Grayson M.A., Spencer D.K., Yoder B.A., Khodr G.S. Effect of excessive GnRH-binding substance on circulating maternal hCG in human pregnancy. Early Pregnancy. 1997; 3: 10-4.
  50. Herman A., Ron-El R., Golan A., Nachum H., Soffer Y., Caspi E. Impaired corpus luteum function and other undesired results of pregnancies associated with inadvertent administration of a long-acting agonist of gonadotrophin-releasing hormone. Hum. Reprod. 1992; 7(4): 465-8.
  51. Thau R.B. Luteinizing hormone-releasing hormone (LHRH) and its analogs for contraception in women: a review. Contraception. 1984; 29: 143-62.
  52. Hugues J.N., Cedrin-Durnerin I., Bstandig B., Theron-Gerard L., Grange D., Laffy A. et al. Administration of gonadotropin-releasing hormone agonist during the luteal phase of GnRH-antagonist IVF cycles. Hum. Reprod. 2006; 21: i3.
  53. Klemmt P.A., Liu F., Carver J.G., Jones C., Brosi D., Adamson J. et al. Effects of gonadotrophin releasing hormone analogues on human endometrial stromal cells and embryo invasion in vitro. Hum. Reprod. 2009; 24: 2187-92.
  54. Chou C.S., Tai C.J., MacCalman C.D., Leung P.C. Dose-dependent effects of gonadotropin releasing hormone on matrix metalloproteinase (MMP)-2, and MMP-9 and tissue specific inhibitor of metalloproteinases-1 messenger ribonucleic acid levels in human decidual stromal cells in vitro. J. Clin. Endocrinol. Metab. 2003; 88: 680-8.
  55. Zhang X., Bocca S., Franchi A., Anderson S., Kaur M., Bajic V.B., Oehninger S. Do GnRH analogues directly affect human endometrial epithelial cell gene expression? Mol. Hum. Reprod. 2010; 16(5): 347-60.
  56. Balasch J., Martinez F., Jove I., Cabré L., Coroleu B., Barri PN., Vanrell J.A. Inadvertent gonadotrophin-releasing hormone agonist (GnRHa) administration in the luteal phase may improve fecundity in in-vitro fertilization patients. Hum. Reprod. 1993; 8: 1148-51.
  57. Elefant E., Biour B., Blumberg-Tick J., Roux C., Thomas F. Administration of a gonadotropin-releasing hormone agonist during pregnancy: follow-up of 28 pregnancies exposed to triptoreline. Fertil. Steril. 1993; 63: 1111-3.
  58. Gartner B., Moreno C., Marinaro A., Remohi J., Simon C., Pellicer A. Accidental exposure to daily long-acting gonadotrophin-releasing hormone analogue administration and pregnancy in an in-vitro fertilization cycle. Hum. Reprod. 1997; 12: 2557-9.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2014
##common.cookie##